Latest news with #Consensus
Yahoo
15 hours ago
- Business
- Yahoo
Why Danaher (DHR) is a Top Growth Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time. Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. It is headquartered in Washington, DC. DHR sits at a Zacks Rank #3 (Hold), holds a Growth Style Score of B, and has a VGM Score of B. Earnings and sales are forecasted to increase 2.9% and 2.7% year-over-year, respectively. Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0.06 to $7.70 per share. DHR also boasts an average earnings surprise of 8.5%. On a historic basis, Danaher has generated cash flow growth of 12.1%, and is expected to report cash flow expansion of 0.8% this year. Investors should take the time to consider DHR for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Danaher Corporation (DHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
15 hours ago
- Business
- Yahoo
Embraer Secures Contract From SkyWest to Supply 60 E175 Jets
Embraer S.A. ERJ recently clinched a contract from SkyWest Inc. for delivering 60 of its E175 aircraft, with purchase rights for 50 additional aircraft. These jet deliveries are expected to start in 2027. The aforementioned orders should boost Embraer's future revenue stream and bolster its profitability. The E-175 is a regional jet recognized for its fuel efficiency, superior avionics and spacious cabin. It is also appreciated for its comfort, operational agility and short to medium-distance trips. It offers seating for 76-88 passengers and features a flying range of 2,200 nautical miles (4,074 km).Due to such remarkable features, Embraer must have been witnessing a steady inflow of orders for this jet model. The recent order placed by SkyWest is a bright example. Rising air passenger traffic, backed by enhanced air travel among passengers and executives, along with the increasing demand for fuel-efficient and modern aircraft, is driving growth in the commercial aviation market. This is likely to have prompted the Mordor Intelligence firm to forecast a CAGR of 6.5% for the commercial aviation market during the 2025-2030 period. Such solid market growth projections boost demand for fuel-efficient jets like those manufactured by Commercial Aviation segment backlog at the end of the first quarter of 2025 was $10 billion. Such a strong backlog not only reflects the consistent demand for ERJ's aircraft from commercial airlines, like the latest one, but also strengthens the company's revenue generation prospects. Other aerospace stocks that stand to benefit from the growing commercial aviation market are as follows:Airbus SE EADSY: It is one of the forerunners in the global commercial aircraft space. Its order backlog amounted to 8,726 commercial aircraft at the end of March 2025, while the company delivered 243 commercial jets to 61 customers up to May has a long-term (three to five years) earnings growth rate of 4%. The Zacks Consensus Estimate for EADSY's 2025 sales suggests a year-over-year improvement of 10.4%.The Boeing Company BA: It has been a premier manufacturer of commercial jetliners for decades. Its Commercial Airplanes segment delivered 220 airplanes up to May 2025. This unit had a backlog of $460.4 billion as of March 31, has a long-term earnings growth rate of 18.1%. The Zacks Consensus Estimate for BA's 2025 sales suggests a year-over-year improvement of 25.6%.Textron Inc. TXT: Its Textron Aviation unit is a well-known designer of business jet brands like Cessna and Beechcraft. The segment's order backlog as of March 29, 2025 was $7.9 billion. The unit delivered 31 Citation jets and 30 commercial turboprops in the first quarter of boasts a long-term earnings growth rate of 10%. The Zacks Consensus Estimate for TXT's 2025 sales calls for a year-over-year improvement of 6.6%. In the past six months, Embraer shares have risen 47.1% compared with the industry's growth of 15.5%. Image Source: Zacks Investment Research Embraer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Embraer-Empresa Brasileira de Aeronautica (ERJ) : Free Stock Analysis Report Textron Inc. (TXT) : Free Stock Analysis Report Airbus Group (EADSY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Aurora Cannabis Inc. (ACB) Misses Q4 Earnings Estimates
Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -36.36%. A quarter ago, it was expected that this company would post earnings of $0.04 per share when it actually produced earnings of $0.06, delivering a surprise of 50%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Aurora Cannabis , which belongs to the Zacks Medical - Products industry, posted revenues of $63.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.65%. This compares to year-ago revenues of $49.98 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Aurora Cannabis shares have added about 38.4% since the beginning of the year versus the S&P 500's gain of 1.7%. While Aurora Cannabis has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Aurora Cannabis: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.17 on $69.13 million in revenues for the coming quarter and $0.44 on $268.33 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Abbott (ABT), has yet to report results for the quarter ended June 2025. This maker of infant formula, medical devices and drugs is expected to post quarterly earnings of $1.25 per share in its upcoming report, which represents a year-over-year change of +9.7%. The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. Abbott's revenues are expected to be $11.05 billion, up 6.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
13-06-2025
- Business
- Yahoo
Apple stock could catch a short-term bid with cheap valuation: Morgan Stanley
-- Apple shares may benefit from short-term upside as deep discounting in China fuels stronger-than-expected iPhone and iPad sales, according to Morgan Stanley. 'iPhone and iPad sell-through in China are positively surprising this quarter thanks to 618 Festival promotion momentum,' Morgan Stanley analysts wrote, adding that the trend suggests 'up to $4B June revenue upside vs. MSe, all else equal.' 'Specifically, we now see ~3.0M units of upside to our June quarter iPhone shipments and ~2.5M units of upside to our June quarter iPad shipments,' the bank stated. China's 618 Festival promotions and national subsidies are said to have been key drivers, leading to 'very strong' iPhone sell-through for three consecutive weeks. The bank's Greater China Tech Hardware team now estimates 46.5 million iPhone builds and 14.5 million iPad builds in the June quarter, representing year-over-year growth of 19% and 38%, respectively. That's up from prior estimates of 45 million iPhones and 13 million iPads. Using historical seasonal relationships between builds and shipments, Morgan Stanley projects iPhone shipments to hit 49 million, which is '7% above MSe of 46.0M units, and 8% above Consensus at 45.2M.' For iPads, they now see 14.7 million shipments, '20% above MSe of 12.3M units, and 12% above Consensus.' While near-term Services growth uncertainty remains a concern for investors, Morgan Stanley stated: 'Estimate upside is typically accompanied by multiple expansion, so watch for Apple (NASDAQ:AAPL) to potentially catch a short-term bid given the stock is trading towards the lower-end of its 24-32x P/E range over the last 2 years.' Related articles Apple stock could catch a short-term bid with cheap valuation: Morgan Stanley Brookfield Infrastructure reportedly acquiring Hotwire for $7 billion Nvidia GTC Paris is 'another bullish proof point' long term - Morgan Stanley Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
DOCU Shares Fall 18.2% Despite Q1 Earnings & Revenue Beat
DocuSign, Inc. DOCU reported impressive first-quarter fiscal 2026 results, wherein earnings per share (EPS) and revenues surpassed the Zacks Consensus Estimate. However, the better-than-expected results failed to impress the investors, as the stock has lost 18.2% since the company released results on June 5. Image Source: Zacks Investment Research DOCU's EPS (excluding 56 cents from non-recurring items) was 90 cents, which surpassed the Zacks Consensus Estimate by 11.1% and increased 9.8% from the year-ago quarter. Total revenues of $763.7 million beat the consensus mark by 2.2% and rose 7.6% from the first quarter of fiscal 2025. The company's shares have rallied 49.6% in the past year compared with the industry's 37.3% rise and the Zacks S&P 500's 10.8% growth. Image Source: Zacks Investment Research Subscription revenues totaled $746.2 million, increasing 8% year over year. The figure beat our estimate of $730.4 million. Professional services and other revenues of $17.5 million fell 4% from the year-ago quarter, beating our expectation of $17 million. Billings amounted to $739.6 million, up 4% from the year-ago quarter. The figure failed to meet our anticipation of $748.7 million. The non-GAAP gross margin was 82.3%, beating our estimate of 81.4%. The non-GAAP gross profit of $628.7 million grew 8% year over year and outpaced our expectation of $608.4 million. The non-GAAP operating margin was 29.5%, increasing 100 basis points from the year-ago quarter. It beat our estimate of 27.6%. DocuSign exited the first quarter of fiscal 2026 with cash and cash equivalents of $657.4 million compared with $817.4 million at the end of the first quarter of fiscal 2025. Net cash generated by operating activities was $251.4 million for the reported quarter. Free cash flow generated was $227.8 million. For the second quarter of fiscal 2026, the company expects revenues between $777 million and $781 million. The mid-point of the guided range ($779 million) is above the Zacks Consensus Estimate of $777.7 million. DOCU anticipates subscription revenues in the range of $760-$764 million and billing revenues between $757 million and $767 million. The non-GAAP gross margin and the non-GAAP operating margin are expected to be 80.5-81.5% and 26.5-27.5%, respectively. For fiscal 2026, the company expects revenues between $3.15 billion and $3.16 billion. The Zacks Consensus Estimate for the same is $3.15 billion. DOCU anticipates subscription revenues between $3.08 billion and $3.09 billion and billings between $3.29 billion and $3.34 billion. The non-GAAP gross margin and the non-GAAP operating margin are expected to be 80.7-81.7% and 27.8-28.8%, respectively. Currently, DocuSign carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Fiserv, Inc. FI reported mixed first-quarter 2025 results. The company's earnings beat the Zacks Consensus Estimate, while revenues missed the mark. FI's adjusted earnings per share of $2.14 beat the consensus mark by 2.9% and gained 13.8% year over year. Adjusted revenues of $4.8 billion lagged the consensus estimate by 1.6% but rose 5.5% on a year-over-year basis. (See the Zacks Earnings Calendar to stay ahead of market-making news.) The Interpublic Group of Companies, Inc. IPG reported mixed first-quarter 2025 results. The company's earnings topped the Zacks Consensus Estimate, while revenues missed the mark. IPG's adjusted earnings of 33 cents per share surpassed the Zacks Consensus Estimate by 10% but decreased 8.3% from the year-ago quarter. Revenues before billable expenses (net revenues) of $2 billion missed the consensus estimate by a slight margin and declined 20% year over year. Total revenues of $2.3 billion decreased 7.2% year over year but beat the Zacks Consensus Estimate of $2 billion. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Interpublic Group of Companies, Inc. (The) (IPG) : Free Stock Analysis Report Fiserv, Inc. (FI) : Free Stock Analysis Report Docusign Inc. (DOCU) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
